<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04582084</url>
  </required_header>
  <id_info>
    <org_study_id>ETA.ARY.AJ.93</org_study_id>
    <nct_id>NCT04582084</nct_id>
  </id_info>
  <brief_title>Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis</brief_title>
  <acronym>ASQA</acronym>
  <official_title>Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis (ASQA): a Multicenter Post-marketing Surveillance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AryoGen Pharmed Co.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AryoGen Pharmed Co.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this open-label, multi-center, observational, post-marketing surveillance study, patients&#xD;
      with ankylosing spondylitis, psoriatic arthritis, or rheumatoid arthritis received biosimilar&#xD;
      etanercept 25 mg twice weekly or 50 mg once weekly in real-world settings. Safety and&#xD;
      effectiveness of biosimilar etanercept were evaluated in study participants for a duration of&#xD;
      up to 12 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this open-label, multi-center, observational, post-marketing surveillance study, patients&#xD;
      with ankylosing spondylitis, psoriatic arthritis, or rheumatoid arthritis received biosimilar&#xD;
      etanercept 25 mg twice weekly or 50 mg once weekly in real-world settings. Safety and&#xD;
      effectiveness of biosimilar etanercept were evaluated in study participants for a duration of&#xD;
      up to 12 months. Patient information was recorded in four notebooks, and each notebook had&#xD;
      three sections, one section for each month. The first section of notebook I contained&#xD;
      demographic information, pregnancy and lactation status in female patients, cigarette smoking&#xD;
      and alcohol consumption, and past medical history. All safety and effectiveness outcomes were&#xD;
      recorded at the appropriate sections of the notebooks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2014</start_date>
  <completion_date type="Actual">March 19, 2018</completion_date>
  <primary_completion_date type="Actual">March 19, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: incidence of adverse events</measure>
    <time_frame>Throughout the study period (up to 12 months for each patient)</time_frame>
    <description>All adverse events, including serious adverse events, are reported using system organ classes and preferred terms of the medical dictionary for regulatory activities (MedDRA Desktop Browser 4.0 Beta).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health assessment questionnaire (HAQ)-score</measure>
    <time_frame>Baseline, 3, 6, 9, and 12 months</time_frame>
    <description>Health assessment questionnaire (HAQ) is a functional test used in patients with a wide variety of rheumatic diseases, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. HAQ score ranges from 0 to 3, with higher scores indicating more severe functional disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>Baseline, 3, 6, 9, and 12 months</time_frame>
    <description>Pain assessment is performed on a scale of 0 to 10, with higher scores indicating greater pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global assessments of disease activity (PGA)</measure>
    <time_frame>3, 6, 9, and 12 months</time_frame>
    <description>Patient global assessment of disease activity (PGA) is a very common patient reported outcome measure used in rheumatic disorders. PGA assessment is performed on a scale of 0 to 10, with higher scores indicating higher disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician global assessment of disease activity (PhGA)</measure>
    <time_frame>3, 6, 9, and 12 months</time_frame>
    <description>Physician global assessment of disease activity (PhGA) is used to assess disease severity by physicians. PhGA assessment is performed on a scale of 0 to 10, with higher scores indicating higher disease activity.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">583</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Autoimmune Arthritis</arm_group_label>
    <description>Patients with autoimmune arthritis, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis, receiving biosimilar etanercept in real-world settings</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Patients received biosimilar etanercept 25 mg twice weekly or 50 mg once weekly.</description>
    <arm_group_label>Autoimmune Arthritis</arm_group_label>
    <other_name>Biosimilar etanercept</other_name>
    <other_name>Altebrel</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis&#xD;
        receiving biosimilar etanercept (either 25 mg or 50 mg) for their medical condition were&#xD;
        eligible for this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults with the diagnosis of rheumatoid arthritis, ankylosing spondylitis, or&#xD;
             psoriatic arthritis receiving biosimilar etanercept (either 25 mg or 50 mg) for their&#xD;
             medical condition.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No strict exclusion criteria were applied.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmadreza Jamshidi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rheumatology Research Center, Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Connective Diseases Research Center, Tabriz University of Medical Sciences</name>
      <address>
        <city>Tabriz</city>
        <state>East Azerbaijan</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hafez Hospital</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Razi Hospital</name>
      <address>
        <city>Rasht</city>
        <state>Guilan</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ghaem Hospital</name>
      <address>
        <city>Mashhad</city>
        <state>Khorasan</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golestan Hospital</name>
      <address>
        <city>Ahvaz</city>
        <state>Khouzestan</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alzahra Hospital</name>
      <address>
        <city>Isfahan</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Personal Office</name>
      <address>
        <city>Isfahan</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerman University of Medical Sciences</name>
      <address>
        <city>Kerman</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Personal Office</name>
      <address>
        <city>Shiraz</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Research Center, Tehran University of Medical Sciences</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 3, 2020</study_first_submitted>
  <study_first_submitted_qc>October 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>October 13, 2020</last_update_submitted>
  <last_update_submitted_qc>October 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Etanercept</keyword>
  <keyword>Biosimilar</keyword>
  <keyword>Safety</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Ankylosing Spondylitis</keyword>
  <keyword>Psoriatic Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected deidentified individual participant data (IPD) will be shared.</ipd_description>
    <ipd_time_frame>Starting 6 months after publication.</ipd_time_frame>
    <ipd_access_criteria>Data would be shared upon reasonable request from the Study Principal Investigator, without any specific criteria:&#xD;
Ahmadreza Jamshidi Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran Email: dr.ahmadreza.jamshidi@gmail.com Tel: +982188220065</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

